Clinic-Ready Insights on Emerging Data for Current Antibody–Drug Conjugates in Breast Cancer

Deepen your understanding on the mechanisms of action, efficacy, and guideline recommendations for using antibody–drug conjugates to treat breast cancer. This program also includes strategies to integrate patients’ treatment goals and preferences into care plans as well as to help manage therapy-related toxicities through an expert-written ClinicalThought and an on-demand webcast with accompanying downloadable slides.

Share

Supporters

This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.